Cite
Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.
MLA
Zhang, Jie, et al. “Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.” Journal of Managed Care & Specialty Pharmacy, vol. 26, no. 4, Apr. 2020, pp. 417–90. EBSCOhost, https://doi.org/10.18553/jmcp.2020.26.4.417.
APA
Zhang, J., Sridhar, G., Barr, C. E., Eichelberger, B., Lockhart, C. M., Marshall, J., Clewell, J., Accortt, N. A., Curtis, J. R., Holmes, C., McMahill-Walraven, C. N., Brown, J. S., & Haynes, K. (2020). Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance. Journal of Managed Care & Specialty Pharmacy, 26(4), 417–490. https://doi.org/10.18553/jmcp.2020.26.4.417
Chicago
Zhang, Jie, Gayathri Sridhar, Charles E Barr, Bernadette Eichelberger, Catherine M Lockhart, James Marshall, Jerry Clewell, et al. 2020. “Incidence of Serious Infections and Design of Utilization and Safety Studies for Biologic and Biosimilar Surveillance.” Journal of Managed Care & Specialty Pharmacy 26 (4): 417–90. doi:10.18553/jmcp.2020.26.4.417.